幹細胞治療市場 : 2027 年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年9月

幹細胞治療市場 : 種類 (同種、自家)、細胞源 (脂肪組織由来 MSC、骨髄、胎盤/臍帯)、治療用途 (筋骨格、創傷、手術、心血管、神経) – 2027 年までの世界予測
Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) – Global Forecast to 2027

ページ数 160
図表数 198
種別 英文調査報告書
価格 こちらをご覧ください

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The global stem cell therapy market is projected to reach USD 558 million by 2027 from USD 257 million in 2022, at a CAGR of 16.8% during the forecast period. Several companies are focusing on developing regenerative medicine due to the rising number of clinical trials conducted on stem cell therapies. The increasing number of clinical trials has largely taken place owing to the rising government and public & private investments for R&D in cell-based therapies, supportive regulatory framework, and accelerated approval provisions by the FDA in regenerative medicine R&D.

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027

“The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, by type, during the forecast period”
The stem cell therapy market is segmented into allogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. Stem cells used for allogeneic stem cell therapy are obtained from sources other than the target patient, which is usually from a donor. In allogeneic stem cell therapy, one cell source can produce many doses, thus making allogeneic therapy economically viable and less time-consuming. Moreover, it is easier to scale up production processes for allogeneic therapy than for autologous therapy. Currently, more than ten approved commercialized allogeneic stem cell therapies are available globally.

“Bone Marrow-derived MSCs segment accounted for the highest CAGR”
Based on the cell source the global stem cell therapy market is segmented into adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. Bone marrow-derived mesenchymal stem cells are the most preferred type for stem cell therapies. Bone marrow MSCs are readily available, require less in vitro processing, and can be used for autologous and allogeneic stem cell therapy. Over the last decade, the stem cell therapy market has witnessed high demand for several bone marrow-derived stem cell-based products for various therapeutic applications, including immune-deficiency syndromes, hemoglobinopathies, and metabolic disorders. This has collectively contributed the segment’s growth.

“Asia Pacific: The fastest-growing country in the stem cell therapy market”
The stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Rising cases of neurodegenerative disorders drive market growth for stem cell therapy products in India along with favorable government support for stem cell therapy products in South Korea have propelled the growth of Asia Pacific stem cell therapy market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: C-level – 25%, D-level – 20%, and Others – 55%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
Lists of Companies Profiled in the Report:
• Smith+Nephew (UK)
• MEDIPOST Co. Ltd. (South Korea)
• Anterogen Co. Ltd. (South Korea)
• CORESTEM (South Korea)
• Pharmicell Co. Ltd. (South Korea)
• NuVasive Inc. (US)
• RTI Surgical (US)
• AlloSource (US)
• JCR Pharmaceuticals Co. Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• Holostem Terapie Avanzate Srl (Italy)
• Orthofix (US)
• Regrow Biosciences Pvt Ltd. (India)
• STEMPEUTICS RESEARCH PVT LTD. (India)
• Athersys (US)
• Mesoblast Ltd (Australia)
• Biorestorative Therapies Inc. (US)
• Pluristem Inc. (Israel)
• Brainstorm Cell Limited. (US)
• ViaCyte Inc. (US)
• Gamida Cell (US)
• Kangstem Biotech (South Korea)
• Hope Biosciences (US)
• Cellular Biomedicine Group (US)
• Personalized Stem Cells (US)

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027

Research Coverage:
This report provides a detailed picture of the stem cell therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, therapeutic applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.


目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 26)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
FIGURE 1 STEM CELL THERAPY MARKET
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 30)
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: STEM CELL THERAPY MARKET
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF STEM CELL THERAPY MARKET PLAYERS
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
2.3 GROWTH FORECAST
FIGURE 7 STEM CELL THERAPY MARKET: CAGR PROJECTIONS (2022–2027)
FIGURE 8 STEM CELL THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 PRIMARY INSIGHTS
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY (Page No. – 42)
FIGURE 12 STEM CELL THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 13 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2022 VS. 2027 (USD MILLION)
FIGURE 14 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2022 VS. 2026 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF STEM CELL THERAPY MARKET

4 PREMIUM INSIGHTS (Page No. – 46)
4.1 STEM CELL THERAPY MARKET OVERVIEW
FIGURE 16 INCREASING INVESTMENTS & FUNDING INITIATIVES FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: STEM CELL THERAPY MARKET
FIGURE 17 ALLOGENEIC STEM CELL THERAPY TO COMMAND LARGEST SHARE IN 2021
4.3 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2022 VS. 2027 (USD MILLION)
FIGURE 18 BONE MARROW-DERIVED MSCS TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 48)
5.1 INTRODUCTION
FIGURE 19 MARKET DYNAMICS: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Availability of funding for stem cell research
TABLE 1 ICMR FUNDING FOR STEM CELL RESEARCH, 2019–2021 (USD)
FIGURE 20 STEM CELL RESEARCH FUNDING IN LAST 10 YEARS
TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION)
5.2.1.2 Increasing GMP certification approvals for cell therapy production facilities
TABLE 3 NEW GMP FACILITIES, 2017-2020
5.2.1.3 Increasing clinical trials for stem cell-based therapies
FIGURE 21 NUMBER OF CLINICAL TRIALS (2015-2020)
FIGURE 22 CLINICAL TRIALS, BY PHASE
5.2.2 RESTRAINTS
5.2.2.1 Ethical concerns related to embryonic stem cells
5.2.2.2 High cost of cell-based research
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of iPSCs as an alternative to ESCs
5.2.3.2 Growing demand for cell & gene therapies
5.2.4 CHALLENGES
5.2.4.1 Technical limitations associated with manufacturing processes
5.3 TECHNOLOGY ANALYSIS
TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES
5.4 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS OF STEM CELL THERAPY MARKET
5.5 ROLE IN ECOSYSTEM
FIGURE 24 ECOSYSTEM MARKET MAP
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 25 SUPPLY CHAIN ANALYSIS OF STEM CELL THERAPY MARKET
TABLE 5 SUPPLY CHAIN ANALYSIS: COMMERCIAL SCALE/KEY MANUFACTURERS
TABLE 6 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF SUPPLIERS
5.7.4 BARGAINING POWER OF BUYERS
5.7.5 INTENSITY OF COMPETITION RIVALRY
5.8 REGULATORY LANDSCAPE
5.8.1 NORTH AMERICA
TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.8.2 EUROPE
TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.8.3 ASIA PACIFIC
TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.8.4 REST OF THE WORLD
TABLE 10 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.9 PRICING ANALYSIS
5.9.1 PRICING ANALYSIS
TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS
5.9.2 AVERAGE SELLING PRICE TREND – STEM CELL THERAPY TREATMENT
5.10 PATENT ANALYSIS
FIGURE 26 PATENT ANALYSIS OF STEM CELL THERAPIES IN LAST 10 YEARS (2011-2020)
5.11 KEY CONFERENCES & EVENTS IN 2022–2023
5.11.1 STEM CELL THERAPY CONFERENCES (2022–2023)
TABLE 12 STEM CELL THERAPY CONFERENCES (2022–2023)
5.12 DISRUPTIONS & TRENDS IMPACTING CUSTOMERS’ BUSINESSES
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 27 KEY STAKEHOLDERS IN STEM CELL THERAPY MARKET
FIGURE 28 KEY BUYING CRITERIA FOR END USERS
FIGURE 29 REVENUE SHIFT & NEW POCKET FOR STEM CELL THERAPY COMPANIES

6 STEM CELL THERAPY MARKET, BY TYPE (Page No. – 70)
6.1 INTRODUCTION
TABLE 13 STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 ALLOGENEIC STEM CELL THERAPY
6.2.1 FAVORABLE SCALING UP OF PRODUCTION PROCESSES TO DRIVE SEGMENT
TABLE 14 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 15 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 16 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 AUTOLOGOUS STEM CELL THERAPY
6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE SEGMENT
TABLE 18 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 19 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 STEM CELL THERAPY MARKET, BY CELL SOURCE (Page No. – 75)
7.1 INTRODUCTION
TABLE 22 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
7.2 ADIPOSE TISSUE-DERIVED MSCS
7.2.1 PROPERTIES SUCH AS SIMPLIFIED HARVESTING & EASE OF ISOLATION TO DRIVE MARKET
TABLE 23 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION)
TABLE 24 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 25 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 BONE MARROW-DERIVED MSCS
7.3.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET
TABLE 27 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION)
TABLE 28 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS
7.4.1 LOWER CHANCES OF IMMUNE REJECTION TO SUPPORT MARKET
TABLE 31 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 OTHER CELL SOURCES
TABLE 35 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION)

8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION (Page No. – 84)
8.1 INTRODUCTION
TABLE 39 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
8.2 MUSCULOSKELETAL DISORDERS
8.2.1 RISING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET
TABLE 40 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 41 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 WOUNDS & INJURIES
8.3.1 GROWING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH
TABLE 44 STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 46 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 INFLAMMATORY & AUTOIMMUNE DISEASES
8.4.1 INCREASING CLINICAL TRIALS FOR BONE MARROW-DERIVED MSCS TO SUPPORT MARKET GROWTH
TABLE 48 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 49 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 50 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 51 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & INFLAMMATORY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 SURGERIES
8.5.1 GROWING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH
TABLE 52 STEM CELL THERAPY MARKET FOR SURGERIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 EUROPE: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 CARDIOVASCULAR DISEASES
8.6.1 RISING DEMAND FOR CVD TREATMENTS TO SUPPORT MARKET GROWTH
TABLE 56 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
8.7 NEUROLOGICAL DISORDERS
8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS TO SUPPORT MARKET GROWTH
TABLE 60 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 61 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
8.8 OTHER THERAPEUTIC APPLICATIONS
TABLE 64 STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 66 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 ASIA PACIFIC: STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

9 STEM CELL THERAPY MARKET, BY REGION (Page No. – 98)
9.1 INTRODUCTION
TABLE 68 STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 71 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.2.1 US
9.2.1.1 Rising approvals for stem cell therapy products to drive market
FIGURE 31 NIH FUNDING IN LAST 10 YEARS (2011–2021)
TABLE 73 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 74 US: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Increasing government focus on targeted stem cell therapy treatment to drive market
TABLE 76 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 77 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 78 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.3 EUROPE
TABLE 79 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 80 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 81 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Strong R&D base and growing focus on minimally invasive treatments to drive market
TABLE 83 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 84 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.3.2 UK
9.3.2.1 Rising adoption of cell-based therapies to drive market
TABLE 86 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 87 UK: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Rising healthcare expenditure to support uptake of stem cell therapy products
TABLE 89 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 90 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 91 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.3.4 REST OF EUROPE
TABLE 92 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 93 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 94 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 32 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT
TABLE 95 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 96 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Growing geriatric population and rapid regulatory processes to drive market
TABLE 98 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 99 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 100 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.4.2 SOUTH KOREA
9.4.2.1 Favorable government support for stem cell therapy products to support market growth
TABLE 101 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 102 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Rising cases of neurodegenerative disorders drive market
TABLE 104 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 105 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 107 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 108 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)
9.5 REST OF THE WORLD
TABLE 110 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION)
TABLE 111 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. – 122)
10.1 INTRODUCTION
10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
FIGURE 33 STEM CELL THERAPY MARKET: STRATEGIES ADOPTED
10.3 REVENUE SHARE ANALYSIS
10.4 MARKET SHARE ANALYSIS (2021)
10.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS)
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 36 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR APPROVED PRODUCTS (2021)
10.6 COMPETITIVE BENCHMARKING
10.6.1 STEM CELL THERAPY MARKET: A DETAILED LIST OF STARTUPS/SMES
TABLE 113 STEM CELL THERAPY MARKET: DETAILED LIST OF STARTUPS/SMES
10.6.2 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES)
TABLE 114 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES]
10.7 COMPANY EVALUATION QUADRANT (SMES/START-UPS)
10.7.1 PROGRESSIVE COMPANIES
10.7.2 STARTING BLOCKS
10.7.3 RESPONSIVE COMPANIES
10.7.4 DYNAMIC COMPANIES
FIGURE 37 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR PRODUCTS UNDER PIPELINE (2021)
10.8 COMPANY PRODUCT FOOTPRINT ANALYSIS
TABLE 115 COMPANY PRODUCT FOOTPRINT
10.9 COMPANY FOOTPRINT OF MAJOR PLAYERS
TABLE 116 COMPANY REGIONAL FOOTPRINT
10.10 COMPETITIVE SCENARIO
TABLE 117 STEM CELL THERAPY MARKET: REGULATORY APPROVALS
TABLE 118 STEM CELL THERAPY MARKET: DEALS

11 COMPANY PROFILES (Page No. – 135)
11.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 SMITH+NEPHEW
TABLE 119 SMITH+NEPHEW: BUSINESS OVERVIEW
FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2021)
TABLE 120 SMITH+NEPHEW: PRODUCT OFFERINGS
TABLE 121 SMITH+NEPHEW: DEALS
11.1.2 MEDIPOST CO., LTD.
TABLE 122 MEDIPOST CO., LTD: BUSINESS OVERVIEW
FIGURE 39 MEDIPOST CO., LTD: COMPANY SNAPSHOT (2019)
TABLE 123 MEDIPOST CO., LTD: PRODUCT OFFERINGS
TABLE 124 MEDIPOST CO., LTD: PRODUCT APPROVALS
TABLE 125 MEDIPOST CO., LTD: DEALS
TABLE 126 MEDIPOST CO., LTD: OTHERS
TABLE 127 MEDIPOST CO., LTD: REGULATORY APPROVALS AND PATENTS
11.1.3 JCR PHARMACEUTICALS CO., LTD.
TABLE 128 JCR PHARMACEUTICALS CO., LTD: BUSINESS OVERVIEW
FIGURE 40 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021)
TABLE 129 JCR PHARMACEUTICALS CO., LTD: PRODUCT OFFERINGS
11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 130 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW
FIGURE 41 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021)
TABLE 131 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT OFFERINGS
TABLE 132 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS
TABLE 133 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGULATORY APPROVALS
11.1.5 ANTEROGEN. CO., LTD.
TABLE 134 ANTEROGEN CO., LTD: BUSINESS OVERVIEW
TABLE 135 ANTEROGEN CO., LTD: PRODUCT OFFERINGS
11.1.6 CORESTEM
TABLE 136 CORESTEM: BUSINESS OVERVIEW
TABLE 137 CORESTEM: PRODUCT OFFERINGS
TABLE 138 CORESTEM: REGULATORY APPROVALS
11.1.7 PHARMICELL CO., LTD.
TABLE 139 PHARMICELL CO., LTD.: BUSINESS OVERVIEW
TABLE 140 PHARMICELL CO., LTD.: PRODUCT OFFERINGS
TABLE 141 PHARMICELL CO., LTD.: DEALS
11.1.8 NUVASIVE, INC.
TABLE 142 NUVASIVE, INC: BUSINESS OVERVIEW
FIGURE 42 NUVASIVE, INC: COMPANY SNAPSHOT (2021)
TABLE 143 NUVASIVE, INC.: PRODUCT OFFERINGS
11.1.9 RTI SURGICAL
TABLE 144 RTI SURGICAL: BUSINESS OVERVIEW
TABLE 145 RTI SURGICAL: PRODUCT OFFERINGS
11.1.10 ALLOSOURCE
TABLE 146 ALLOSOURCE: BUSINESS OVERVIEW
TABLE 147 ALLOSOURCE: PRODUCT OFFERINGS
11.1.11 HOLOSTEM TERAPIE AVANZATE SRL
TABLE 148 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW
TABLE 149 HOLOSTEM TERAPIE AVANZATE SRL: PRODUCT OFFERINGS
11.1.12 ORTHOFIX
TABLE 150 ORTHOFIX: BUSINESS OVERVIEW
FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2021)
TABLE 151 ORTHOFIX: PRODUCT OFFERINGS
11.1.13 STEMPEUTICS RESEARCH
TABLE 152 STEMPEUTICS RESEARCH: BUSINESS OVERVIEW
TABLE 153 STEMPEUTICS RESEARCH: PRODUCT OFFERINGS
11.1.14 REGROW BIOSCIENCES PVT LTD.
TABLE 154 REGROW BIOSCIENCES PVT LTD: BUSINESS OVERVIEW
TABLE 155 REGROW BIOSCIENCES PVT LTD: PRODUCT OFFERINGS
11.2 OTHER PLAYERS (PRODUCTS IN PIPELINE)
11.2.1 ATHERSYS, INC.
11.2.2 MESOBLAST LTD
11.2.3 BIORESTORATIVE THERAPIES, INC.
11.2.4 PLURISTEM INC.
11.2.5 BRAINSTORM CELL LIMITED.
11.2.6 GAMIDA CELL
11.2.7 VIACYTE, INC.
11.2.8 KANGSTEM BIOTECH
11.2.9 HOPE BIOSCIENCES
11.2.10 CELLULAR BIOMEDICINE GROUP (CBMG)
11.2.11 PERSONALIZED STEM CELLS

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX (Page No. – 161)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com